USPTO Patent Grant: Pyridone Derivative Crystal Form

ChangeBridge: Patent Grants - Organic Chemistry (C07D)

Published March 24th, 2026

Detected March 24th, 2026

Summary

The USPTO has granted a patent to Jiangxi Caishi Pharmaceutical Technology Co., Ltd. for a novel pyridone derivative crystal form and its preparation method. This patent covers specific crystal forms and their application in treating influenza, potentially offering improved efficacy and bioavailability.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has issued patent US12583867B2 for a pyridone derivative crystal form, identified as compound of formula (1), and its preparation method. The patent specifically details various crystal forms (A through F) and single crystals, along with their application in treating influenza. The assignee is Jiangxi Caishi Pharmaceutical Technology Co., Ltd., with Qing Shao, Libin Gan, and Li Chen listed as inventors.

This patent grant signifies a new intellectual property right for the inventors and assignee, potentially impacting the landscape of anti-influenza drug development. While this is a patent grant and not a regulatory rule imposing direct compliance obligations on other entities, it establishes exclusive rights for the patent holder. Companies involved in the development or manufacturing of anti-influenza drugs, particularly those utilizing pyridone derivatives or similar compounds, should be aware of this patent to avoid infringement. The patent claims specific crystal forms and their use in combination with other anti-influenza agents, highlighting potential therapeutic advantages such as rapid clinical cure, good activity, and bioavailability.

Source document (simplified)

← USPTO Patent Grants

Pyridone derivative crystal form and preparation method and application therefor

Grant US12583867B2 Kind: B2 Mar 24, 2026

Assignee

Jiangxi Caishi Pharmaceutical Technology Co., Ltd.

Inventors

Qing Shao, Libin Gan, Li Chen

Abstract

Crystals of (((R)-12′-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl)-6′,8′-dioxo-6′,8′,12′,12a′-tetrahydro-1′H,4′H-spiro[cyclopropane-1,3′-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin]-7′-yl)oxy)methyl methyl carbonate, i.e. compound of formula (1) or a solvate thereof and a preparation method therefor. The crystals include crystal form A, crystal form B, crystal form C, crystal form D, crystal form E, crystal form F, and single crystal. The crystal of the compound of formula (1) or a solvate thereof can be individually used for clinical treatment or in combination with other anti-influenza drugs such as neuraminidase inhibitors, nucleoside drugs, or PB2 inhibitors, are capable of clinically curing influenza patients quickly, and have very good activity and good bioavailability compared to existing pyridone derivatives. In addition, the stability, hygroscopicity, and storability of the crystals meet the requirements for pharmaceutical use.